David Follows promoted to COO

    
  Inion Oy
  10 June 2008
   
    Inion Oy
    ("Inion or the "Company")

    Inion promotes David Follows to Chief Operating Officer

    Tampere, Finland and Guildford, UK. 10 June 2008, Inion (LSE: IIN.L), the company focused on the development and commercialisation of
novel biodegradable medical implants, today announces the promotion of David Follows to the role of Chief Operating Officer.

    David joined Inion in June 2007 as Chief Commercial Officer from ETHICON Endo-Surgery UK, where he was Managing Director. He has more
than 28 years of commercial experience in the medical devices industry, predominantly with subsidiaries of Johnson & Johnson. 

    In his new role, David will be responsible for manufacturing, supply chain, logistics, research & development and quality control, as
well as sales outside the USA and global marketing. He will also be working closely with Chris Lee, CEO, and Dave Hawkes, US National Sales
Director, to drive the Company's commercial success in the important US market.
        
    Chris Lee said, "David's promotion is very well deserved. He has made an excellent contribution to the restructuring and refocusing of
the organisation in the areas under his control and continues to be a highly valued member of the team."

    -ends-

    For further information, please contact:

 Inion Oy                   Tel: +44 (0)1483 685390
 Chris Lee, Chief
 Executive Officer
 Julien Cotta, Chief
 Financial Officer
  
 Citigate Dewe Rogerson      Tel: +44 (0)207 638 9571
 Mark Swallow / David                                
 Dible

    About Inion (www.inion.com)
    Inion Oy is a medical devices company focused on the development and successful commercialisation of innovative and unique biodegradable
and bioactive surgical implants in selected high value orthopaedic market segments. 

    Inion's core expertise and technology lies in the design and manufacture of innovative biodegradable plates, screws, pins and membranes,
which are used to enhance the healing of bone or soft tissue injuries to the skeleton, such as those caused by trauma or by reconstructive
surgery. Inion implants are made from its proprietary Inion Optima* family of biomaterials, with properties tailored for specific surgical
applications, in terms of strength, flexibility and rate of degradation
     
Inion is also focused on developing proprietary new bioactive and biodegradable biomaterials that promote bone healing and accelerate
patient rehabilitation.

    Inion was incorporated in early 2000 and listed on the Official List of the UK Listing Authority in December 2004 (ticker: IIN). The
Company has offices in the UK and USA, and its head office, R&D and production facilities are in Tampere, Finland.

    This announcement includes "forward-looking statements" which include all statements other than statements of historical facts,
including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for
future operations (including development plans and objectives relating to the Group's products), and any statements preceded by, followed by
or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will",
"can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements
involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results,
performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by
such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group
will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ
materially from those in forward-looking statements include those relating to Inion's funding requirements, regulatory approvals, reliance
on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this
announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking
statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based. As a result of these factors, prospective investors are cautioned not to
rely on any forward-looking statement.

This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
NRAKGGMVNGMGRZG
Inion Oy (LSE:IIN)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024